The nation is well on its way to becoming the first Group of Seven nation to legalize adult-use marijuana.

Regulations related to marijuana will dominate Canadian national discussion in the first half of 2018, when every province and territory is expected to finalize cannabis production and sales rules.

Sales could begin before the first leaves fall in September, and marijuana entrepreneurs around the world are scrambling to capitalize on Canada’s legalization. The jostling will likely continue into 2019 and beyond.

3. Alcohol joins the party

Marijuana’s age-old rival, alcohol, is starting to see opportunity instead of threat in the cannabis industry. And the new year could tell alcohol companies whether to step up investments.

One of the biggest alcohol businesses in the world, Constellation Brands, has bought a significant stake in Ontario-based Canopy Growth and is going to enter the recreational cannabis industry when Canada begins sales.

And U.S. beer makers are going to expand their experiments with cannabis.

Lagunitas Brewing in California is adding terpenes to its Supercritical IPA, and other makers are expected to follow suit.

Influential market data analyst GlobalData warned alcohol makers in November that “legalization of recreational marijuana presents a threat, as drinkers may swap alcohol for cannabis.”

Expect more alcohol companies to decide in 2018 to join the cannabis industry instead of fighting it.

4. State legislatures pass rec laws

It’ll be hard to surpass the magnitude of legalization in 2016, with so many states, including California, adopting rec legalization.

But 2018 could be a historic year for legalization as well – not because of the number of states or market size involved, but because of how it comes about: State legislatures passing recreational marijuana laws.

New Jersey, Vermont and Rhode Island are all candidates for the historic honor:

New Jersey lawmakers already have a bill to work with from last session while incoming Gov. Phil Murphy campaigned partly on the promise to legalize adult-use marijuana.

Vermont Gov. Phil Scott, who vetoed a rec bill last year, said in December he’s comfortable with signing a more limited rec bill into law that would permit possession and home growing. And some state lawmakers think it could happen as early as January.

Dark-horse status goes to Rhode Island, where there is strong legislative support for legalization. Gov. Gina Raimondo has been far more reluctant to support rec. But pressure from the looming rec market in neighboring Massachusetts could force her hand.

5. Other states going to ballots

Voters always seem to be ahead of politicians when it comes to cannabis.

And even if legislatures start approving recreational marijuana in 2018, voters in several more states could pass medical or recreational marijuana laws.

MedMen and Poseidon Asset Management, two of the best-known names in the cannabis industry, announced in late October efforts to raise what would be the two largest capital raises in U.S. cannabis industry history – if they are successful.

Closing those kinds of amounts is no easy feat, and MedMen once had to close a fund before it reached its stated goal.

Marijuana observers will also be watching to see if the canna-centric finance firms can land some institutional capital.

7. Don’t forget Congress

As the cannabis industry has expanded, it has naturally gained more allies in Congress.

That growth could culminate in 2018 in perhaps another historic first, with a bipartisan bill to repeal 280E tax restrictions for legal MJ businesses making it to Trump’s desk, or some other measure that would further legitimize the U.S. marijuana sector.

Although there have been dozens of pro-MJ bills introduced in Congress, none has yet received even a full Congressional committee hearing.

But with more and more Republicans coming on board to support varying cannabis bills – which range from outright federal legalization to enabling more scientific research into medical benefits of marijuana – such a victory isn’t nearly as pie-in-the-sky as it was a few years ago.

The opening of the first social-use lounges could trigger an explosion of more.

Many states and jurisdictions say they’re awaiting some guinea pigs before starting their own regulations for social lounges.

By 2019, cannabis clubs could present an entirely new business category in multiple jurisdictions.

10. CBD clarity

The CBD market is going to change dramatically in 2018.

That’s because a lawsuit to be settled in a federal appeals court will determine whether cannabidiol is a controlled substance, as the U.S. Drug Enforcement has said, or whether it is legal as long as it is derived from legal hemp.

The decision could vault CBD products into the mainstream, or limit market opportunities to states where marijuana is legal.

Another CBD question to be settled in 2018 goes back to Canada.

That country is planning to authorize CBD hemp extraction along with adult-use marijuana. It’s a change that has global repercussions.

Canada is thought to be world’s No. 2 hemp producer, and some predict a flood of cheap Canadian hemp-derived CBD products will affect global prices.

11. Health authorities take a look

The global marijuana industry will be keeping a close watch on two health agencies in 2018: the United Nations’ World Health Organization and the U.S. Food and Drug Administration.

The WHO has called a May summit to review cannabis and how it is regulated. The agency doesn’t make law, but its conclusions heavily influence drug policy among its 60-plus member nations.

The agency’s upcoming review of “cannabis extracts and tinctures” could trigger revisions to the 1961 UN Single Convention on Narcotic Drugs. Any revisions could dramatically shake up the global cannabis market.

There’s another cannabis industry-shaking health decision for the United States coming from the FDA.

The agency is due to issue a decision on GW Pharma’s Epidiolex, a cannabis-derived drug aimed at treating two rare kinds of epilepsy.

The FDA’s decision could have ramifications for all marijuana users because cannabis would be the first plant-derived cannabidiol approved by the agency – poking the biggest hole yet in the U.S. position that the cannabis plant has no medical use.

I think all of this is awesome the only sad thing is I cannot afford medical marijuana
there’s a lot of other poor people out there just like me I’m in Arkansas and medical is at the doorstep but there’s nothing I can do but suffer.

One area not being discussed as broadly, but still critical to the evolution of the industry, is the use of analytics, both in the traditional sense (business intelligence) and the emerging sense (applied data science). It will be a race to a scalable operating model, and data is the fuel. This issue is not just regionally specific – if cannabis business owners don’t fully understand the details of their businesses, and don’t make strategic decisions on the basis of real supportive data, they will continue to be perceived as “gro bros”, not fully functional, mature enterprises. Being immature in this area will dramatically impact access to growth funding, and more importantly, obstruct achieving maximum outcomes – whether yields, sales, or inability to use the levers available for optimizing results.